Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The company's product categories are: biologics, which include Crysvita? (burosumab) for the treatment of X-linked hypophosphatemia and Mepsevii? (vestronidase alfa) for the treatment of Mucopolysaccharidosis VII; small molecules, which includes UX007 for the treatment of long-chain fatty acid oxidation disorders; and gene therapy, which includes DTX301 for the treatment of patients with ornithine transcarbamylase deficiency and DTX401 for the treatment of patients with glycogen storage disease type Ia.
  • TickerRARE
  • ISINUS90400D1081
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
 PRESS RELEASE
RARE Ultragenyx Phar... (Health Care)

Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors

Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors NOVATO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced the appointment of Corsee Sanders, Ph.D., to the Board of Directors, effective June 29, 2021. Dr. Sanders, an experienced veteran of the biopharma industry, will serve as an independent director. “Dr. Sanders’ established experience in global clinical development and es...

 PRESS RELEASE
RARE Ultragenyx Phar... (Health Care)

Ultragenyx to Present at Goldman Sachs 42nd Annual Healthcare Conferen...

Ultragenyx to Present at Goldman Sachs 42nd Annual Healthcare Conference NOVATO, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the Goldman Sachs 42nd Annual Healthcare Conference on Thursday, June 10, 2021 at 3:00 PM ET. The live and archived webcast of the presentation will be accessi...

 PRESS RELEASE
RARE Ultragenyx Phar... (Health Care)

Ultragenyx to Present at Jefferies Virtual Healthcare Conference

Ultragenyx to Present at Jefferies Virtual Healthcare Conference NOVATO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:30 PM ET. The live and archived webcast of the presentation will be accessible from the compan...

 PRESS RELEASE
RARE Ultragenyx Phar... (Health Care)

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(...

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) NOVATO, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of non-qualified stock options to purchase an aggregate of 4,677 shares of common stock of the company and 7,100 restricted stock units of the company’s common stock to a newly hired non-executive officer of the company. The awards were approved by the compensation commi...

 PRESS RELEASE
RARE Ultragenyx Phar... (Health Care)

Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors

Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors NOVATO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced the appointment of Corsee Sanders, Ph.D., to the Board of Directors, effective June 29, 2021. Dr. Sanders, an experienced veteran of the biopharma industry, will serve as an independent director. “Dr. Sanders’ established experience in global clinical development and es...

 PRESS RELEASE
RARE Ultragenyx Phar... (Health Care)

Ultragenyx to Present at Goldman Sachs 42nd Annual Healthcare Conferen...

Ultragenyx to Present at Goldman Sachs 42nd Annual Healthcare Conference NOVATO, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the Goldman Sachs 42nd Annual Healthcare Conference on Thursday, June 10, 2021 at 3:00 PM ET. The live and archived webcast of the presentation will be accessi...

 PRESS RELEASE
RARE Ultragenyx Phar... (Health Care)

Ultragenyx to Present at Jefferies Virtual Healthcare Conference

Ultragenyx to Present at Jefferies Virtual Healthcare Conference NOVATO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:30 PM ET. The live and archived webcast of the presentation will be accessible from the compan...

 PRESS RELEASE
RARE Ultragenyx Phar... (Health Care)

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(...

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) NOVATO, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of non-qualified stock options to purchase an aggregate of 4,677 shares of common stock of the company and 7,100 restricted stock units of the company’s common stock to a newly hired non-executive officer of the company. The awards were approved by the compensation commi...

 PRESS RELEASE
RARE Ultragenyx Phar... (Health Care)

Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors

Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors NOVATO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced the appointment of Corsee Sanders, Ph.D., to the Board of Directors, effective June 29, 2021. Dr. Sanders, an experienced veteran of the biopharma industry, will serve as an independent director. “Dr. Sanders’ established experience in global clinical development and es...

 PRESS RELEASE
RARE Ultragenyx Phar... (Health Care)

Ultragenyx to Present at Goldman Sachs 42nd Annual Healthcare Conferen...

Ultragenyx to Present at Goldman Sachs 42nd Annual Healthcare Conference NOVATO, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the Goldman Sachs 42nd Annual Healthcare Conference on Thursday, June 10, 2021 at 3:00 PM ET. The live and archived webcast of the presentation will be accessi...

 PRESS RELEASE
RARE Ultragenyx Phar... (Health Care)

Ultragenyx to Present at Jefferies Virtual Healthcare Conference

Ultragenyx to Present at Jefferies Virtual Healthcare Conference NOVATO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:30 PM ET. The live and archived webcast of the presentation will be accessible from the compan...

 PRESS RELEASE
RARE Ultragenyx Phar... (Health Care)

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(...

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) NOVATO, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of non-qualified stock options to purchase an aggregate of 4,677 shares of common stock of the company and 7,100 restricted stock units of the company’s common stock to a newly hired non-executive officer of the company. The awards were approved by the compensation commi...

 PRESS RELEASE
RARE Ultragenyx Phar... (Health Care)

Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors

Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors NOVATO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced the appointment of Corsee Sanders, Ph.D., to the Board of Directors, effective June 29, 2021. Dr. Sanders, an experienced veteran of the biopharma industry, will serve as an independent director. “Dr. Sanders’ established experience in global clinical development and es...

 PRESS RELEASE
RARE Ultragenyx Phar... (Health Care)

Ultragenyx to Present at Goldman Sachs 42nd Annual Healthcare Conferen...

Ultragenyx to Present at Goldman Sachs 42nd Annual Healthcare Conference NOVATO, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the Goldman Sachs 42nd Annual Healthcare Conference on Thursday, June 10, 2021 at 3:00 PM ET. The live and archived webcast of the presentation will be accessi...

 PRESS RELEASE
RARE Ultragenyx Phar... (Health Care)

Ultragenyx to Present at Jefferies Virtual Healthcare Conference

Ultragenyx to Present at Jefferies Virtual Healthcare Conference NOVATO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:30 PM ET. The live and archived webcast of the presentation will be accessible from the compan...

 PRESS RELEASE
RARE Ultragenyx Phar... (Health Care)

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(...

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) NOVATO, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of non-qualified stock options to purchase an aggregate of 4,677 shares of common stock of the company and 7,100 restricted stock units of the company’s common stock to a newly hired non-executive officer of the company. The awards were approved by the compensation commi...

 PRESS RELEASE
RARE Ultragenyx Phar... (Health Care)

Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors

Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors NOVATO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced the appointment of Corsee Sanders, Ph.D., to the Board of Directors, effective June 29, 2021. Dr. Sanders, an experienced veteran of the biopharma industry, will serve as an independent director. “Dr. Sanders’ established experience in global clinical development and es...

 PRESS RELEASE
RARE Ultragenyx Phar... (Health Care)

Ultragenyx to Present at Goldman Sachs 42nd Annual Healthcare Conferen...

Ultragenyx to Present at Goldman Sachs 42nd Annual Healthcare Conference NOVATO, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the Goldman Sachs 42nd Annual Healthcare Conference on Thursday, June 10, 2021 at 3:00 PM ET. The live and archived webcast of the presentation will be accessi...

 PRESS RELEASE
RARE Ultragenyx Phar... (Health Care)

Ultragenyx to Present at Jefferies Virtual Healthcare Conference

Ultragenyx to Present at Jefferies Virtual Healthcare Conference NOVATO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:30 PM ET. The live and archived webcast of the presentation will be accessible from the compan...

 PRESS RELEASE
RARE Ultragenyx Phar... (Health Care)

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(...

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) NOVATO, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of non-qualified stock options to purchase an aggregate of 4,677 shares of common stock of the company and 7,100 restricted stock units of the company’s common stock to a newly hired non-executive officer of the company. The awards were approved by the compensation commi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch